The Biden administration’s first major step toward imposing limits on the pharmacy benefit managers who act as the drug industry’s price negotiators is backfiring, pharmacists say.
Keytruda combination treatment for NSCLC falls short in Phase III – Pharmaceutical Technology
Share this article The Keytruda / Lynparza treatment is being studied as a first-line treatment for certain types of patients with NSCLC. Credits: Sonis Photography/Shutterstock.com